Pharmaceutical

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

TYRA-200 is under clinical development by Tyra Biosciences and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma).

Jun 20, 2024 - 04:00
TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
TYRA-200 is under clinical development by Tyra Biosciences and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma).
Read the original article

Tags:

Previous Article

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of App...

Next Article

EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Vertex non-opioid therapy reduced pain in mid-stage trials, study shows

STAT+: Vertex non-opioid therapy reduced pain in mid-st...

Aug 3, 2023

STAT+: Pharmalittle: FDA declines to approve higher dose version of Regeneron eye drug; FDA warns wholesaler over counterfeit HIV pills

STAT+: Pharmalittle: FDA declines to approve higher dos...

Jun 28, 2023

STAT+: New Medicare Advantage rule is boon for providers, drag on insurers

STAT+: New Medicare Advantage rule is boon for provider...

Feb 5, 2024